Free Newsletter
Roche's CellCept linked to birth defects
The FDA is warning doctors and patients that CellCept, a drug for organ transplant patients, can cause miscarriages and birth defects. Made by Roche, CellCept will get a "black box" warning that it's been linked to first-trimester pregnancy loss and ear and mouth defects in infants.
Roche cited 25 miscarriages among 77 women exposed to the drug during pregnancy between 1995 and 2007; 14 of the women had babies with birth defects. However, to put this in perspective, more than 450,000 men and women have taken the drug since its 1995 approval.
- read the Houston Chronicle article for more
Related Articles:
Aspreva, Roche put CellCept on ice. Report
Aspreva's CellCept fails late-stage superiority study. Report
Aspreva Pharmaceuticals drug fails Phase III trial. Report
CellCept wins orphan status. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment